Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has type 2 diabetes mellitus~* Male~* Female that is highly unlikely to become pregnant~* Patient is not on an antihyperglycemic agent (AHA) (hemoglobin A1c \[A1C\] 7-10%) or on oral single AHA or low-dose combination therapy (A1C 6.5-9.0%)~Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis~* Patient has required insulin therapy within the past 12 weeks~* Patient is on or has been taking a Peroxisome Proliferator-Activated Receptor-gamma (PPAR -gamma) agent (i.e. Thiazolidinediones \[TZDs\]) within the prior 12 weeks of the screening visit.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: drug
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: active comparator
- 3 (Type: EXPERIMENTAL): Arm 3: drug + active comparator
- 4 (Type: PLACEBO_COMPARATOR): Arm 4: placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).